Sangamo Therapeutics, Inc. (SGMO) Posts Earnings Results, Beats Estimates By $0.04 EPS

The Firm has clinical and preclinical programs in development and partnered certain programs with biopharmaceutical companies to expedite clinical and commercial development. Vanguard Group Inc. owned about 4.83% of Sangamo Therapeutics worth $30,551,000 at the end of the most recent reporting period.

Several other institutional investors have also modified their holdings of the stock. Highbridge Capital Management LLC acquired a new position in shares of Sangamo Therapeutics in the 1st quarter valued at $496,000. About 3.08M shares traded or 120.00% up from the average. (SGMO), the percentage of institutional ownership is now at 62.21% percent of its total shares outstanding, with the total value of institutional ownership at $621574601 billion. Bank of New York Mellon Corp increased its position in shares of Sangamo Therapeutics by 2.0% in the 2nd quarter. Panagora Asset Mgmt holds 2,693 shares. Sangamo Therapeutics, Inc. has 83.61 million shares outstanding, and in the last trade has seen ATR around 0.78. The company has market cap of $1.17 billion. 15,000 RSP Permian Inc (NYSE:RSPP) shares with value of $542,850 were bought by GRAY STEVEN D. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Following the transaction, the vice president now directly owns 23,991 shares in the company, valued at approximately $250,466.04. The disclosure for this sale can be found here.

Aveo Pharmaceuticals (NASDAQ:AVEO)'s shares slipped -4.58% in the past week and plunged -22.75% in the last 4 weeks, historically the stock illustrate that its six months performance stands at 408.98% while its year to date performance is at 440.74%. Insiders own 5.50% of the company's stock.

Within those holders, 81 of them increased their positions - representing 14,460,939 shares of Sangamo Therapeutics, Inc. (SGMO) opened at $12.30 on Friday. The company now has a Return on Equity (ROE) of 0 and a Return on Investment (ROI) of -243.8. Sangamo Therapeutics (NASDAQ:SGMO)'s distance from 20 day simple moving average is-0.0621 along with distance from 50 day simple moving average of 14.02 whereas its distance from 200 day simple moving average is 10.23. The mean target price as estimated by the analysts for the company has been recorded at $14.60.

Sen. Bill Cassidy withdraws support for Roy Moore over sexual misconduct allegations
Gibson has also shared information on facebook promoting Democrat Doug Jones' candidacy for US Senate. Kasich dismissed the the Moore campaign's assertion that the allegations are politically motivated.

Total debt to equity ratio of Sangamo Therapeutics (NASDAQ:SGMO) for most recent quarter is 0.02 whereas long term debt to equity ratio for most recent quarter is 0.02. The firm's revenue was up 333.0% compared to the same quarter previous year. It last reported revenues of $1.25 billion and EPS of $0.08 for the September 2017, representing -4% top-line growth and 0.11 EPS growth.

COPYRIGHT VIOLATION WARNING: "Sangamo Therapeutics, Inc". If you happen to be reading this article on another website, it was stolen and illegally republished in violation of U.S. and worldwide copyright law. Finally, Federated Investors Inc.

The market capitalization (Stock Price Multiply by Total Number of Outstanding Shares) for the company is reported at $1.03B. Zacks Investment Research lowered shares of Sangamo Therapeutics from a "buy" rating to a "hold" rating in a research note on Tuesday, July 18th. Below is a list of Sangamo Therapeutics Inc (NASDAQ:SGMO) latest ratings and price target changes. ValuEngine raised shares of Sangamo Therapeutics from a "sell" rating to a "hold" rating in a research note on Friday, August 11th. Wells Fargo & Company restated an "outperform" rating and issued a $30.00 price objective (up previously from $20.00) on shares of Sangamo Therapeutics in a report on Tuesday, September 5th. One research analyst has rated the stock with a sell rating, three have assigned a hold rating and four have assigned a buy rating to the company. The most optimistic analyst sees the stock reaching $7 while the most conventional predicts the target price at $5.

Have you taken a look at the chart for Sangamo Therapeutics, Inc. The Company is focused on translating science into genomic therapies that transform patients' lives using the Company's platform technologies in genome editing, gene therapy, gene regulation and cell therapy.

Latest News